Longevity & AgingPARP Inhibitor Talazoparib Drives Cancer Cell Senescence in Lung Tumors
Researchers at the University of Namur tested five clinically used PARP inhibitors in non-small cell lung carcinoma (NSCLC) cell lines and found that Talazoparib was the most potent inducer of therapy-induced senescence. Senescent cancer cells showed hallmark features including enlarged morphology, increased SA-β-Gal activity, and reduced Lamin B1. Crucially, PARP1 protein was required for senescence induction — knocking it out abolished the effect. When senescent cells were then targeted with Navitoclax, a senolytic drug that disables anti-apoptotic proteins, cell death increased significantly. These findings suggest that PARP inhibitors in lung cancer therapy may inadvertently create treatment-resistant senescent cells, and that combining them with senolytics could be a strategy to overcome this resistance.
